protein

Recombinant Human MICB protein

MICB-08H

Recombinant Human MICB protein

Creative Biomart

MICB

major histocompatibility complex, class I, B

HLA-B; major histocompatibility complex, class I, B; ankylosing spondylitis , AS; lymphocyte antigen; MHC class I antigen SHCHA; MHC Class I HLA heavy chain; MHC class I antigen GN00104; leukocyte antigen class I-B; MHC HLA-B cell surface glycoprotein; MH

Recombinant Human MIC-B produced in E.coli is a protein with 326 amino acid residues containing the extracellular domain of mature human MICB (amino acid residues Ala23 Tyr312) and having a molecular mass of approximately 37 kDa.

Recombinant Human MIC-B produced in E.coli is a protein with 326 amino acid residues containing the extracellular domain of mature human MICB (amino acid residues Ala23 Tyr312) and having a molecular mass of approximately 37 kDa.MIC-B (MHC class I chain-related gene B) is a transmembrane glycoprotein that functions as a ligand for human NKG2D. A closely related protein, MIC-A, shares 85% amino acid identity with MIC-B. These 2 proteins are distantly related to the MHC class I proteins. MIC-A and MIC-B (MIC-A/B) possess three extracellular immunoglobulin-like domains, but have no capacity to bind peptide or interact with 2-microglobulin. The genes encoding MIC-A/B are found within the major histocompatibility complex on human chromosome 6. The MIC-B locus is polymorphic with more than 15 recognized human alleles. MIC-A/B are minimally expressed on normal cells, but are frequently expressed on epithelial tumors and can be induced by bacterial and viral infections.MIC-A/B are ligands for NKG2D, an activating receptor expressed on NK cells, NKT cells, T cells, and CD8+ T cells. Recognition of MIC-A/B by NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells. MIC-A/B recognition is involved in tumor surveillance, viral infections, and autoimmune diseases. The release of soluble forms of MIC-A/B from tumors down-regulates NKG2D surface expression on effector cells resulting in the impairment of anti-tumor immune response.

95% by SDS-PAGE and HPLC analyses.

This lyophilized preparation is stable at 2-8 C, but should be kept at -20 C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 C to -70 C. Avoid repeated freeze/thaw cycles.